Drug Trial Radar · NCT00630032
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
Last checked: Nov 19, 2026Latest source record: Feb 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
762
Actual
Start
Sep 2007
Primary completion
Jun 2017
Study completion Sep 3, 2020
Sponsor
- Lead sponsor
- UNICANCERAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 6, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them after surgery may kill any tumor cells remaining after surgery. It is not yet known whether docetaxel is more effective than ixabepilone when given after surgery and combination chemotherapy in treating breast cancer. PURPOSE: This randomized phase III trial is studying giving combination chemotherapy followed by docetaxel or ixabepilone to compare how well they work in treating patients who have undergone surgery for nonmetastatic breast cancer.
Conditions
- Breast Cancer
Interventions
cyclophosphamideDrug
500 mg/m² every 3 weeks
DocetaxelDrug
100 mg/m² every 3 weeks
epirubicin hydrochlorideDrug
100 mg/m² every 3 weeks
fluorouracilDrug
500 mg/m² every 3 weeks
ixabepiloneDrug
40 mg/m² every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Disease-free Survival (DFS)Time frame: At 5 years
Locations
86 sites in 3 countries. Site status is shown where the registry gives one.
Mayo Clinic Scottsdale
Scottsdale, Arizona
CCOP - Colorado Cancer Research Program
Denver, Colorado
Mayo Clinic - Jacksonville
Jacksonville, Florida
CCOP - Northern Indiana CR Consortium
South Bend, Indiana
CCOP - Cedar Rapids Oncology Project
Cedar Rapids, Iowa
Siouxland Hematology-Oncology Associates, LLP
Sioux City, Iowa
Cancer Center of Kansas, PA - Wichita
Wichita, Kansas
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota
Southeast Nebraska Hematology Oncology Consultants at Southeast Nebraska Cancer Center
Lincoln, Nebraska
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska
Roger Maris Cancer Center at MeritCare Hospital
Fargo, North Dakota
CCOP - Dayton
Dayton, Ohio
CCOP - Geisinger Clinic and Medical Center
Danville, Pennsylvania
Oncology Associates at Rapid City Regional Hospital
Rapid City, South Dakota
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin
Institut Jules Bordet
Brussels, Belgium
Centre de Sante des Fagnes
Chimay, Belgium
Centre Hospitalier Hutois
Huy, Belgium
Cazk Groeninghe - Campus Maria's Voorzienigheid
Kortrijk, Belgium
CHR - Clinique Saint Joseph - Hopital de Warqueguies
Mons, Belgium
Clinique Saint-Pierre
Ottignies, Belgium
Clinique Universitaire De Mont-Godinne
Yvoir, Belgium
Clinique Claude Bernard
Albi, France
Centre Paul Papin
Angers, France
Centre Hospitalier d'Annecy
Annecy, France
Centre Hospitalier d'Auxerre
Auxerre, France
Institut Sainte Catherine
Avignon, France
Centre Hospitalier de Blois
Blois, France
Institut Bergonie
Bordeaux, France
Clinique Tivoli
Bordeaux, France
Centre Hospitalier Docteur Duchenne
Boulogne-sur-Mer, France
Centre Hospitalier de Fleyriat
Bourg-en-Bresse, France
CHU Hopital A. Morvan
Brest, France
Centre Regional Francois Baclesse
Caen, France
Centre Hospitalier Regional de Chambery
Chambéry, France
Centre Hospitalier de Chateaubriant
Châteaubriant, France
Centre Jean Perrin
Clermont-Ferrand, France
Clinique des Cedres
Cornebarrieu, France
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.